The framework of host protective immunological pathways is provided in this article. Clonal anergy is mediated by IgD B cells and rδ T cells. rδ1 T cells are for clonal anergy for food in intestine, rδ2 T cells are for clonal anergy for self-antigens, and rδ3 T cells are for clonal anergy for food metabolites in liver.Host immune responses can be categorized into eradicable immune reactions and tolerable immune reactions. Eradicable immune responses are triggered by follicular helper T cells and include TH1, TH2a, TH2b, TH22, and THalpha/beta. Tolerable immune responses are triggered by regulatory T cells and include TH1-like, TH9, TH17, and TH3. TH1/TH1-like immune reactions are host protective immunities against intracellular micro-organisms (bacteria, fungi, and protozoa). TH2a/TH2b/TH9 immune reactions are host protective immunities against parasites. TH2a is the immunity against endoparasites (helminths). TH2b is the immunity against ectoparasites (insects). TH22/TH17 immune reactions are host protective immunities against extracellular micro-organisms (bacteria, fungi, and protozoa). THalpha/beta/TH3 immune reactions are host protective immunities against infectious particles (viruses and prions). Based on this framework of host immunological pathways, we can find out that pro-tumor immune response is mainly TH1-like immune response and anti-tumor immune response is mainly THalpha/beta immune response. If know that cancer is associated with an immune dysfunctional disorder, we can develop therapeutic strategies to diagnose or treat solid tumors.
","journal":null,"year":null,"id":653986,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1706616,"name":"Wan-Chung Hu","orcid":"0000-0003-1360-1422","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Cancer as an immune dysfunctional disorder: pro-tumor TH1-like immune response and anti-tumor THalpha/beta immune response based on the complete updated framework of host immunological pathways","abstract":"The framework of host protective immunological pathways is provided in this article. Clonal anergy is mediated by IgD B cells and rδ T cells. rδ1 T cells are for clonal anergy for food in intestine, rδ2 T cells are for clonal anergy for self-antigens, and rδ3 T cells are for clonal anergy for food metabolites in liver.Host immune responses can be categorized into eradicable immune reactions and tolerable immune reactions. Eradicable immune responses are triggered by follicular helper T cells and include TH1, TH2a, TH2b, TH22, and THalpha/beta. Tolerable immune responses are triggered by regulatory T cells and include TH1-like, TH9, TH17, and TH3. TH1/TH1-like immune reactions are host protective immunities against intracellular micro-organisms (bacteria, fungi, and protozoa). TH2a/TH2b/TH9 immune reactions are host protective immunities against parasites. TH2a is the immunity against endoparasites (helminths). TH2b is the immunity against ectoparasites (insects). TH22/TH17 immune reactions are host protective immunities against extracellular micro-organisms (bacteria, fungi, and protozoa). THalpha/beta/TH3 immune reactions are host protective immunities against infectious particles (viruses and prions). Based on this framework of host immunological pathways, we can find out that pro-tumor immune response is mainly TH1-like immune response and anti-tumor immune response is mainly THalpha/beta immune response. If know that cancer is associated with an immune dysfunctional disorder, we can develop therapeutic strategies to diagnose or treat solid tumors.
","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19162232","pmcid":null,"openalex_id":"https://openalex.org/W4281638418","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.31219/osf.io/r872g","host_type":""},{"url":"https://doi.org/10.31219/osf.io/r872g","host_type":""},{"url":"http://doi.org/10.31219/OSF.IO/R872G","host_type":"repository"}],"fields_of_study":["Virus-based gene therapy research","Cancer Immunotherapy and Biomarkers","vaccines and immunoinformatics approaches"],"mesh_terms":[],"keywords":["Immune system","Biology","Immunology","Immunity","Antigen"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T02:37:02.155353Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}